On December 3, 2023, during an episode of TheStreet’s Stocks & Markets Podcast, Michael Breen, CEO of GT Biopharma, discussed the company’s approach to developing a more humane cancer treatment. Hosted by veteran investor Chris Versace, the podcast highlighted the significant growth potential within the biopharmaceutical cancer market, projected to rise from approximately $225 million in 2024 to potentially exceed $360 billion by the years 2030 to 2034. This surge is attributed to increasing cancer incidences, advancements in therapy, and the aging population.
Breen emphasized the need for innovative treatment options, stating, “We want to find a more humane cure for cancer,” referring to existing treatments that have not evolved significantly since the post-World War II era. He elaborated on the traditional treatment methods available to patients, which include surgery, chemotherapy, and radiotherapy.
Surgery often involves invasive procedures that may not eliminate the cancer entirely due to its potential spread through the bloodstream. Chemotherapy, described by Breen as “poisoning your blood,” can cause severe side effects, including a compromised immune system, leading to increased vulnerability to infections. Radiotherapy, on the other hand, involves damaging healthy tissue as it targets cancer cells.
Breen introduced GT Biopharma’s innovative treatment, which utilizes a protein-based drug that can be administered through intravenous infusion or subcutaneous injection. He highlighted that this method offers a significantly more humane alternative to conventional treatments, stating, “It doesn’t involve cutting, doesn’t involve poisoning, doesn’t involve burning.”
The company plans to submit an investigational new drug application to the U.S. Food & Drug Administration either by the end of 2023 or early January 2024, with hopes of commencing clinical trials in the first half of 2026. Breen noted that the focus will be on targeting the most prevalent solid tumors, including bladder cancer, pancreatic cancer, ovarian cancer, lung cancer, head and neck cancer, as well as breast and prostate cancers.
Breast cancer is particularly concerning, affecting one in eight women, while prostate cancer similarly impacts one in eight men. Breen expressed confidence in the company’s approach, stating, “We’re targeting the biggest, most prolific cancers with a humane drug.”
The CEO also addressed the cost-effectiveness of their treatment, asserting that it presents a significant advantage over existing therapies. “Our drug does not have any problems with toxicity,” he explained, adding that its protein-based nature makes it easier to manufacture and more appealing to health insurers.
When discussing potential global opportunities, Breen acknowledged that cancer is a universal challenge, affecting individuals regardless of geographical location. “It doesn’t matter whether you’re from Australia or Singapore or America,” he said, highlighting the company’s intention to establish relationships with clinical trial centers worldwide.
As a mergers and acquisitions attorney, Breen approaches GT Biopharma with a strong focus on commercialization and intellectual property. He assured stakeholders that efforts are being made to secure patents globally, reinforcing the integrity and potential of the company’s innovations.
Breen concluded by mentioning that GT Biopharma has several promising candidates in its pipeline, emphasizing the importance of conducting thorough due diligence. “We have some very interesting tech,” he stated, indicating potential advancements in cancer treatment on the horizon.
